Opiates and infection

Journal of Neuroimmunology

Volumn 83, Issue 1-2, 1998, Pages 4-18

  Risdahl, Jack M ^a   Khanna, Kristen V ^a   Peterson, Phillip K ^a   Molitor, Thomas W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bacteria; Drugs of abuse; Immunosuppression; Morphine; Opiates; Virus

Indexed keywords

NALOXONE; OPIATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; GASTROINTESTINAL INFECTION; HEPATITIS; HUMAN; INFECTION; INTRAVENOUS DRUG ABUSE; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; SEPSIS;

COMMUNICABLE DISEASES; HUMANS; OPIOID-RELATED DISORDERS; RISK FACTORS; VIRUS DISEASES;

EID: 0032520648     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00216-6     Document Type: Article

References (196)

1. Alcabes P., Friedland G. Injection drug use and human immunodeficiency virus infection. Clin. Infect. Dis. 20:1995;1467-1469.
2. Alpert P.L., Munsiff S.S., Gourevitch M.N., Greenberg B., Klein R.S. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin. Infect. Dis. 24:1997;661-668.
3. Armstrong D. History of opportunistic infection in the immunocompromised host. Clin. Infect. Dis. 17:1993;S318-321.
4. Arnold E.F.S. On the uses of opium in shock, reaction and inflammations. Am. J. Med. Sci. LI:1866;212-213.
5. Baker A., Kochan N., Dixon J., Wodak A., Heather N. HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone treatment. Addiction. 90:1995;545-554.
6. Barnes P.F., Bloch A.B., Davidson P.T., Snider D.E. Tuberculosis in patients with human immunodeficiency virus. N. Engl. J. Med. 324:1991;1644-1650.
7. Bartholomew, C., Cleghorn, F., Hull, B., Battoo, K., Diaz, C., Blattner, W., 1990. VI International Conference on AIDS, Final Program and Abstracts, Vol. 1, [abstract Th.C.681], June 20-21. San Francisco, CA, p. 295.
8. Bayer, B.M., Flores, C.M., 1990. Effects of morphine on lymphocyte function: possible mechanisms of interaction. In: Watson, R.R. (Ed.), Drugs of Abuse and Immune Function. CRC Press, Boca Raton, FL, pp. 151-173.
9. Bergstein J.M., Baker E.J., Aprahamian C., Schein M., Wittmann D.H. Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology and treatment. Am. Surg. 61:1995;1105-1108.
10. Bernard, C., 1957. An Introduction to the Study of Experimental Medicine. Dover Publications, New York, NY, p. 100.
11. Biggam A.G. Malignant malaria associated with the administration of heroin intravenously. Trans. R. Soc. Trop. Med. Hyg. 23:1929;147.
12. Bonnet F., Bilaine J., Lhoste F., Mankikian B., Kerdelhue B., Rapin M. Naloxone therapy of human septic shock. Crit. Med. 13:1985;972-975.
13. Boschini A., Smacchia C., Di Fine M., Schiesari A., Ballarini P., Arlotti M., Gabrielli C., Castellani G., Genova M., Pantani P., Lepri A.C., Rezza G. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection, incidence, etiologies, and clinical aspects. Clin. Infect. Dis. 23:1996;107-113.
14. Boyle R.K. Herpes simplex labialis after epideural or parenteral morphine, a randomized, prospective trial in an Australia obstetrics population. Anesth. Intensive Care. 23:1995;433-437.
15. Brancato V., Delvecchio G., Simone P. Survival and mortality in a cohort of heroin addicts in 1985-1994. Minerva Med. 86:1995;97-99.
16. Briggs J.H., McKerron C.E., Souhami R.L., Taylor D.J.E., Andrews H. Severe systemic infections complicating mainline heroin addiction. Lancet. II:1967;1227-1231.
17. Brown S.M., Stimmel B., Taub R.N., Kochwa S., Rosenfield R.E. Immunological dysfunction in heroin addicts. Arch. Int. Med. 134:1974;1001-1006.
18. Brundage J.F. Epidemiology of HIV infection and AIDS in the United States. Dermatol. Clin. 9:1991;443-452.
19. Buchbinder, S., Hessol, S., Lifson, A., 1990. Does infection with hepatitis B virus or vaccination with plasma-derived hepatitis B vaccine accelerate progression to AIDS? VI International Conference on AIDS, Final Program and Abstracts, Vol. 1, [abstract Th.C.679], June 20-21. San Francisco, CA, p. 294.
20. Calkins, A., 1871. Opium and the Opium Appetite, with Notices of Alcoholic Beverages, Cannabis indica, Tobacco and Coca, and Tea and Coffee, in their Hygienic Aspects and Pathologic Relations. J.B. Lippincott, Philadelphia, PA, pp. 23-27.
21. Cantacuzene J. Nouvelles recherches sur le mode de destruction des vibrions dans l'organisme. Ann. de l'Inst. Pasteur. 12:1898;273.
22. Casellas A.M., Guardiola H., Renaud F.L. Inhibition by opioids of phagocytosis in peritoneal macrophages. Neuropeptides. 18:1991;35-40.
23. Centers for Disease Control, 1989. Tuberculosis and human immunodeficiency virus infection. Recommendation of the advisory committee for the elimination of tuberculosis (ACET). MMWR, 38, 236-250.
24. Centers for Disease Control, 1995. Wound botulism - California, 1995. MMWR, 44, 889-892.
25. Chandrasekar, P.H., 1991. Skeletal infections among intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, p. 305.
26. Chao C.C., Sharp B.M., Pomeroy C., Filice G.A., Peterson P.K. Lethality of morphine in mice infected with Toxoplasma gondii. J. Pharmacol. Exp. Ther. 252:1990;605-609.
27. Chao C.C., Sharp B.M., Pomeroy C., Filice G.A., Peterson P.K. Effects of morphine addiction on the pathogenesis of murine toxoplasmosis. Adv. Exp. Med. Biol. 288:1991;223-227.
28. Cherubin C.E. Infectious disease problems of narcotic addiction. Arch. Int. Med. 128:1971;309-313.
29. Cherubin C.E., Milliam S.J. Serological investigations in heroin addicts. Ann. Int. Med. 69:1968;739-742.
30. Christenson, J.C., Hill, H.R., 1994. Infections complicating congenital immunodeficiency syndromes. In: Rubin, R.H., Young, L.S. (Eds.), Clinical Approach to Infection in the Compromised Host, 3rd edn. Plenum Medical Book, New York, NY, p. 521.
31. Chuang L.F., Killiam K.F. Jr., Chuang R.Y. Increased replication of simian immunodeficiency virus in CEM×174 cells by morphine sulfate. Biochem. Biophys. Res. Commun. 195:1993;1165-1173.
32. Clark D. Surgical management of infections and other complications from drug abuse. Arch. Surg. 101:1970;619-623.
33. Coll G.E., Lewis H. Metastatic choroidal abscesses and choroidal neovascular membrane associated with Staphylococcus aureus endocarditis in a heroin user. Retina. 14:1994;256-259.
34. Coronedi, G., Giarre, C., Borri, L., Biondi, G., 1897. Su di un caso di avvelenamento per morfina complicato da polmonite. Lo 'Zacchia' Ommagio al prof, F. Firenze, p. 135. Arch. Ital. de Biol., 29, p. 245.
35. Coronedi, G., Giarre, C., Borri, L., Biondi, G., 1897. Su di un caso di avvelenamento per morfina complicato da polmonite. Lo 'Zacchia' Ommagio al prof, F. Firenze, p. 135. Arch. Ital. de Biol., 29, p. 245.
36. Crane, L.R., 1991. Epidemiology of infections in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 3-26.
37. Crone L.A., Conly J.M., Clark K.M., Crichlow A.C., Wardell G.C., Zbitnew A., Rea L.M., Crank S.L., Anderson C.M., Tan L.K.et al. Recurrent herpes simplex virus labialis and the use of epidermal morphine in obstetric patients. Anesth. Analg. 67:1988;318-323.
38. Crothers, T.D., 1902. Morphinism and Narcomanias from Other Drugs, their Etiology, Treatment and Medicolegal Relations. Saunders, Philadelphia, PA, pp. 1-352.
39. Cushman P. Persistent increased immunoglobulin M in treated narcotic addiction. J. Allergy Clin. Immunol. 52:1973;122-128.
40. Cushman P., Grieco M.H. Hyperimmunoglobulinemia associated with narcotic addiction, effects of methadone maintenance treatment. Am. J. Med. 54:1973;320-326.
41. Cushman P., Sherman C. Biologic false-positive reactions in serologic tests for syphilis in narcotic addiction. Am. J. Clin. Pathol. 61:1974;346-351.
42. D'Amato R., Holaday J.W. Multiple opioid receptors in endotoxic shock, evidence for delta involvement and mu-interactions in vivo. Proc. Natl. Acad. Sci., USA. 81:1984;2898-2901.
43. Davis S.D., McDonald W.J., Kendall J.W., Potter D.M. Endotoxic shock, prevented by naloxone in intact but not hypophosectomized rats. Proc. Soc. Exp. Biol. Med. 175:1984;380-385.
44. DeCarolis C., DeSanctis G., Perricone R., Moretti C., Fabbri A., Gnessi L., Fraioli F., Fontana L. Evidence for an inhibitory role of beta-endorphin and other opioids on human total T rosette formation. Experientia. 40:1984;738-739.
45. DeMaria A., Carven D.E., Heffernan J.J., McIntosh T.K., Grindlinger G.A., McCabe W.R. Naloxone versus placebo in treatment of septic shock. Lancet. 1:1985;1363-1365.
46. Des Jarlais D.C., Paone D., Friedman S.R., Peyser N., Newman R.G. Regulating controversial programs for unpopular people, methadone maintenance and syringe needle exchange program. Am. J. Public Hlth. 85:1995;1577-1584.
47. Diaz T., Chu S.Y., Byers R.H., Hersh B.S., Conti L., Rietmeijer C.A., Mokotoff E., Fann S.A., Boyd D., Iglesias L.et al. The types of drugs used by HIV-infected injection drug users in a multi-state surveillance project and implications for intervention. Am. J. Public Hlth. 84:1994;1971-1975.
48. Doane J.C. Tetanus as a complication in drug inebriety. J.A.M.A. 82:1924;1105-1111.
49. Donahoe R.M., Nicholson J.M., Madden J.J., Donahoe F., Shafer D.A., Gordon D., Bokas P., Falek A. Coordinate and independent effects of heroin, cocaine and alcohol abuse on T-cell E-rosette formation and antigenic marker expression. Clin. Immunol. Immunopathol. 41:1986;250-264.
50. Donahoe R.M., Bueso-Ramos C., Falek A., McClure H., Nicholson J.K. Comparative effects of morphine on leukocytic antigenic markers of monkeys and humans. J. Neurosci. Res. 19:1988;157-165.
51. Donahoe R.M., Falek A., Madden J.J., Nicholson J.K., Bokos P., Gallegos K., Veit R. Effects of cocaine and other drugs of abuse on immune function. Adv. Exp. Med. Biol. 288:1991;143-150.
52. Donahoe R.M., Byrd L.D., McClure H.M., Fultz P., Brantley M., Marsteller F., Ansari A.A., Wenzel D., Aceto M. Consequences of opiate dependency in a monkey model of AIDS. Adv. Exp. Med. Biol. 335:1993;21-28.
53. Donaldson M.D., Vesey C.J., Wilks M., Hinds C.J. Beneficial effects of buprenorphine (a partial opiate agonist) in porcine Escherichia coli septicemia, a comparison with naloxone. Circ. Shock. 25:1988;209-221.
54. Dziki A.J., Lynch W.H., Ramsey C.B., Law W.R. Beta-adrenergic-dependent and -independent actions of naloxone on perfusion during endotoxic shock. Circ. Shock. 39:1993;29-38.
55. Eisenstein, T.K., Hilburger, M.E., Lawrence, D.M.P., 1996. Immunomodulation by morphine and other opioids. In: Friedman, H., Klein, T.W., Specter, S. (Eds.), Drugs of Abuse, Immunity and Infections. CRC Press, Boca Raton, FL, pp. 103-120.
56. Elk R., Grabowski J., Rhoades H., Spiga R., Schmitz J., Jennings W. Compliance with tuberculosis treatment in methadone-maintained patients, behavioral interventions. J. Subst. Abuse Treat. 10:1993;371-382.
57. Ernst A.A., Farley T.A., Martin D.H. Screening and empiric treatment for syphilis in an inner-city emergency department. Acad. Emerg. Med. 2:1995;765-772.
58. Facy F. Epidemiological aspects of drug addiction, morbidity and evaluation of care. Rev. Prat. 45:1995;1345-1350.
59. Fisch M.A., Daikos G.L., Uttamchandani R.B.et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple drug resistant bacilli. Ann. Int. Med. 117:1992;184-190.
60. Gale E.F. Effects of narcotics on Staphylococcus aureus. J. Gen. Microbiol. 55:1969;8-9.
61. Geiger, J.C., 1934. Malaria in narcotic addicts. 98, pp. 1494-1497.
62. Gieraerts R.A., Navalgund L.V., Vaes L., Soetens M., Chang J.L., Jahr J. Increased incidence of itching and herpes simplex in patients given epidural morphine after Caesarean section. Anesth. Anal. 66:1987;1321-1324.
63. Gilardi G.L. Infrequently encountered Pseudomonas species causing infections in humans. Ann. Int. Med. 77:1972;211-215.
64. Gold J.W.M., Telzak E.E., Armstrong D. Overview of patients with T-cell defects. Clin. Infect. Dis. 17:1993;S414-15.
65. Greville, H.W., 1991. Pulmonary infections in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Oxford Univ. Press, New York, NY, pp. 209-249.
66. Grieco M.H., Chuang C. Hypermacroglobulinemia associated with heroin use in adolescents. J. Allergy Clin. Immunol. 51:1973;152-160.
67. Hagan H., Des Jarlais D.C., Friedman S.R., Purchase D., Alter M.J. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am. J. Public Hlth. 85:1995;1531-1537.
68. Hahn H., Schweid A., Beaty H. Complications of injecting dissolved methylphenidate tablets. Arch. Int. Med. 123:1969;656-659.
69. Haverkos H.W., Lange R.W. Serious infections other than human immunodeficiency virus among intravenous drug users. J. Infect. Dis. 161:1990;894-902.
70. Hecht S.S., Friedman J. The high incidence of cervical dental caries among drug addicts. Oral Surg. Oral Med. Oral Pathol. 2:1949;1428-1442.
71. Helpern M. Epidemic of fatal estivo-autumnal malaria among drug addicts in New York City transmitted by common use of hypodermic syringe. Am. J. Surg. 26:1934;111-123.
72. Hershow R.C., Galai N., Fukuda K., Graber J., Vlahov D., Rezza G., Klein R.S., Des Jarlais D.C., Vitek C., Khabbaz R., Freels S., Zuckerman R., Pezzotti P., Kaplan J.E. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type I disease progression in injection drug users. J. Infect. Dis. 174:1996;309-317.
73. Hewlet, A.W., 1916. Monographic Medicine. D. Appelton, New York, NY, pp. 1185-1186.
74. Hinshaw L.B., Archer L.T., Beller B.K., Chang A.C., Flournoy D.J., Passey R.B., Long J.B., Holaday J.W. Evaluation of naloxone therapy for Escherichia coli sepsis in the baboon. Arch. Surg. 123:1988;700-704.
75. Holaday J.W., D'Amato R.J. Multiple opioid receptors, evidence for mu-delta binding site interactions in endotoxic shock. Life Sci. 33:1983;703-706.
76. Holaday J.W., Faden A.I. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature. 275:1978;450-451.
77. Holaday J.W., D'Amato R.J., Ruvio B.A., Feuerstein G., Faden A.I. Adrenalectomy blocks pressor responses to naloxone in endotoxic shock, evidence for sympathomedullary involvement. Circ. Shock. 11:1983;201-210.
78. Hughes W.T. Prevention of infections in patients with T-cell defects. Clin. Infect. Dis. 17:1993;S368-371.
79. Hussey H., Katz S. Infections resulting from narcotic addiction. Am. J. Med. 9:1950;186-193.
80. Hussey H.H., Keliher T.F., Schaefer B.F., Walsh B.J. Septicemia and bacterial endocarditis resulting from heroin addiction. J. Am. Med. Assoc. 126:1944;535-538.
81. Karch, S.B., 1993. The Pathology of Drug Abuse. CRC Press, Boca Raton, FL, p. 293.
82. Kauffman, C.A., Bradley, S.F., 1991. Host defense mechanisms in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 27-33.
83. Kee T.H. The habitual use of opium as a factor in the production of diseases. Phil. J. Sci. 3:1908;63-67.
84. Kobayashi S. Clinical and experimental research on the changes in the teeth and the soft tissue of the mouth cavity following habitual drug addiction. Jpn. J. Med. Sci. 8:1935;42-44.
85. Koyuncouglu H., Ang O., Inanc D., Sagduyu H., Gungor M. The inhibition by morphine and D-aspartic acid of antibody production against Salmonella typhimurium antigen in rats, its antagonism by L-aspartic acid. Agents Actions. 20:1987;93-97.
86. Kraft A., Leitch N.M. The action of drugs in infection, the influence of morphine in experimental septicemia. J. Pharm. Exp. Ther. 17:1921;377-384.
87. Kreek M.J. Medical safety and side effects of methadone in tolerant individuals. J.A.M.A. 223:1973;665-668.
88. Kreek, M.J., 1973b. Physiological implications of methadone treatment. In: Methadone Treatment Manual, U.S. Department of Justice 2700-00227. Washington, DC, pp. 85-91.
89. Kreek M.J. Opioid interactions with alcohol. Adv. Alcohol Subst. Abuse. 3:1984;35-46.
90. Kreek M.J. Immune function in heroin addicts and former heroin addicts in treatment, pre- and post-AIDS epidemic. NIDA Res. Monogr. 96:1990;192-219.
91. Kruegar H., Eddy N.B., Sumwalt M. The pharmacology of opium alkaloids. Public Hlth. Rep. Suppl. 165:1941;1-1448.
92. Lancelin R. Morphinisme et infections, rôle des leucocytes (étude expérimentale). Rev. Neurol. 11:1903;675.
93. Law F.E., Ruble J.W. Dental caries in morphine addicts. Public Hlth. Rep. 28:1950;1336-1340.
94. Lee, C.A., Phillips, A.N., Elford, J., Janossy, G., Griffeths, P.D., Kernoff, P.B.A., 1990. Ten-year follow-up of a cohort of 111 anti-HIV seropositive haemophiliacs. VI International Conference on AIDS, Final Program and Abstracts, Vol. 1, [abstract Th.C.641], June 20-21. San Francisco, CA, p. 285.
95. Lee, H.K., Bluestone, H., Frances, R., 1994. Screening and treatment of tuberculosis in a methadone maintenance treatment program. Hosp. Community Psychiatry, 45, pp. 759-760/p. 764.
96. Leshin L.S., Malven P.V. Bacteremia-induced changes in pituitary hormone release and effect of naloxone. Am. J. Physiol. 247:1984;E585-591.
97. Levine, D.P., 1991a. Infectious endocarditis in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 251-285.
98. Levine, D.P., 1991b. Skin and soft tissue infections in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 183-207.
99. Light A.B., Torrence E.G. Opium addiction, physical characteristics and physical fitness of addicts during administration of morphine. Arch. Int. Med. 43:1929;326-329.
100. Lippman M.L., Goldberg S.K., Walkenstein M.D., Herring W., Gordon M. Bacteremic pneumococcal pneumonia, a community hospital experience. Chest. 108:1995;1608-1613.
101. Liu Y., Blackbourn D.J., Chuang L.F., Killam K.F. Jr., Chuang R.Y. Effects of in vivo and in vitro administration of morphine sulfate upon rhesus macaque polymorphonuclear cell phagocytosis and chemotaxis. J. Pharmacol. Exp. Ther. 263:1992;533-539.
102. Lohr K.M. Rheumatic manifestations of diseases associated with substance abuse. Seminar Arthritis Rheum. 17:1987;90-111.
103. Lopez M.C., Chen G.J., Colombo L.L., Huang D.S., Darban H.R., Watzl B., Watson R.R. Spleen and thymus cell subsets modified by long-term morphine administration and murine AIDS-II. Int. J. Immunopharmacol. 8:1993;909-918.
104. Louria D.B. Medical complications of pleasure-giving drugs. Arch. Int. Med. 123:1969;82-87.
105. Louria D.B., Hensle T., Rose J. Major medical complications of heroin addiction. Ann. Int. Med. 67:1967;1-22.
106. Lysle D.T., Coussins M.E., Watts V.J., Bennett E.H., Dykstra K.A. Morphine-induced alterations of immune status, dose-dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265:1993;1071-1078.
107. Makman M.H. Morphine receptors in immunocytes and neurons. Adv. Neuroimmunol. 4:1994;69-82.
108. Mazzone A., Mazzucchelli I., Fossati G., Gritti D., Fea M., Ricevuti G. Granulocyte defects and opioid receptors in chronic exposure to heroin or methadone in humans. Int. J. Immunopharmacol. 16:1995;959-967.
109. Mazzone A., Fossati G., Mazzucchelli T., Gritti D., Canule C., Ricevuti G. Opioid receptors and phagocyte defects in drug addicts. Recenti Progressi In Medicina (Italy). 87:1996;530-537.
110. Meldon A. Death from tetanus induced by a hypodermic injection. Brit. Med. J. 2:1879;709.
111. Merry J., Gompels B.M. Miliary tuberculosis of ribs, heroin addiction. Brit. J. Psych. 116:1970;645-646.
112. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilipis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment, an 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 6:1993;1049-1056.
113. Molitor T.W., Morilla A., Risdahl J.M., Murtaugh M.P., Chao C.C., Peterson P.K. Chronic morphine administration impairs cell-mediated immune responses in swine. J. Pharm. Exp. Ther. 260:1992;581-586.
114. Murray M.J., Offord K.P., Yaksh T.L. Physiologic and plasma hormone correlates of survival in endotoxic dogs, effects of opiate antagonists. Crit. Care Med. 17:1989;39-47.
115. Mutchnick, M.G., Lee, H.H., Pelleman, R.R., 1991. Liver disease associated with intravenous drug abuse. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 286-305.
116. Naess F., Waage A., Roeise O., Stadaas J.O., Aasen A.O. Effects of a combined drug regimen on tumor necrosis factor and plasma kallikrein activity in experimental endotoxemia. Eur. J. Surg. 160:1994;77-96.
117. Nishijima M.K., Breslow M.J., Miller C.F., Traystman R.J. Effect of naloxone and ibuprofen on organ blood flow during endotoxic shock in the pig. Am. J. Physiol. 255:1988;H177-184.
118. Norman B. Tetanus after hypodermic injection of morphine. Lancet. 1:1876;873.
119. Novick D.M., Khan I., Kreek M.J. Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. U.N. Bull. Narc. 38:1986;15-25.
120. Novick, D.M., Ochshorn, M., Kreek, M.J., 1991. In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts. In: Friedman, H., et al. (Eds.), Drugs of Abuse, Immunity, and Immunodeficiency. Plenum, New York, NY, pp. 159-170.
121. Ochelsha B., Przedpelska G. The course of early syphilis in morphine base-dependent rabbits. Przegl Dermatol. 76:1989;247-255.
122. O'Connor P.G., Selwyn P.A., Schottenfeld R.S. Medical care for injection-drug users with human immunodeficiency virus infection. N. Engl. J. Med. 331:1994;450-459.
123. Oppel, W.A., 1902. Beitrag zur frage der beeinflussung der immunität durch opium. Med. Woche, 3, pp. 373-375/pp. 383-385.
124. Orangio G.R., DellaLatta P., Marino C., Guarneri J.J., Giron J.A., Palmer J., Margolis I.B. Infections in parenteral drug abusers, further immunological studies. Am. J. Surg. 146:1983;738-741.
125. Orangio G.R., Pitlick S.D., DellaLatta P., Mandel L.J., Marino C., Guarneri J.J., Giron J.A., Margolis I.B. Soft tissue infections in parenteral drug abusers. Ann. Surg. 199:1984;97-100.
126. Osburne C.A. Tetanus due to puncture of a hypodermic needle in a drug addict. Brit. Med. J. 2:1892;75.
127. Panasiak W., Gumulka S., Kobus M., Luczak M. The influence of morphine on development of HSV-1 and M-MSV virus infection in mice. Acta Microbiol. Pol. 39:1990;215-218.
128. Pellis N.R., Harper C., Dafny N. Suppression of the induction of delayed hypersensitivity in rats by repetitive morphine treatments. Ex. Neurol. 93:1986;92-97.
129. Pennant J.H., Wallace D. Intrathecal morphine and reactivation of oral herpes simplex. Anesthesiology. 75:1991;167.
130. Perez-Castrillon J.L., Perez-Arellano J.L., Garcia-Palomo J.D., Jimenez-Lopez A., De-Castro S. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacology. 23:1992;57-61.
131. Perlman D.C., Salomon N., Perkins M.P., Yancovitz S., Paone D., Des Jarlais D.C. Tuberculosis in drug users. Clin. Infect. Dis. 21:1995;1253-1264.
132. Peters W.P., Johnson M.W., Fridman P.A., Mitch W.E. Pressor effect of naloxone in septic shock. Lancet. 1:1981;529-532.
133. Peterson P.K., Sharp B., Gekker G., Brummit C., Keane W.F. Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J. Immunol. 138:1987;3907-3912.
134. Peterson P.K., Sharp B., Gekker G., Brummit C., Keane W.F. Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J. Clin. Invest. 80:1987;824-831.
135. Peterson, P.K., Molitor, T.W., Chao, C.C., Sharp, B., 1990a. Opiates and cell-mediated immunity. In: Watson, R.R. (Ed.), Drugs of Abuse and Immune Function. CRC Press, Boca Raton, FL, pp. 1-18.
136. Peterson P.K., Sharp B.M., Gekker G., Portoghese P.S., Sannerud K., Balfour H.H. Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS. 4:1990;869-873.
137. Peterson P.K., Molitor T.W., Chao C.C. Mechanisms of morphine-induced immunomodulation. Biochem. Pharm. 46:1993;343-348.
138. Peterson, P.K., Gekker, G., Schul, R., Hu, S., Balfour, H.H., Chao, C.C., 1993b. Enhancement of HIV-1 replication by opiates and cocaine, the cytokine connection. In: Friedman, H., Klein, T., Specter, S. (Eds.), Drugs of Abuse, Immunity and AIDS. Plenum, New York, NY, pp. 181-188.
139. Peterson P.K., Gekker G., Hu S., Anderson W.R., Kravitz F., Portoghese P.S., Balfour H., Chao C.C. Morphine amplifies HIV-1 expression in chronically infected promonocytes co-cultured with human brain cells. J. Neuroimmunol. 50:1994;167-175.
140. Pitchenik A.E., Fertel D., Bloch A.B. Mycobacterial disease, epidemiology, diagnosis, treatment and prevention. Clin. Chest. Med. 9:1988;425-441.
141. Poet T.S., Martinez F., Watson R.R. Effect of murine retroviral infection on hair and serum levels of cocaine and morphine. Forensic Sci. Int. 54:1992;29-38.
142. Pollard R. Surgical implications of some types of drug dependents. Brit. Med. J. 283:1973;764-767.
143. Rajs J., Karlsson T., Eklund B., Bergendahl K. HIV-related deaths outside medical institutions in Stockholm. Forensic Sci. Int. 41:1989;269-280.
144. Reichman L.B., Felton C.P., Edsall J.R. Drug dependence, a possible new risk factor for tuberculosis disease. Arch. Int. Med. 139:1979;337-339.
145. Rho Y.M. Infections as fatal complications of narcotics. N.Y. State J. Med. 271:1972;823-828.
146. Riedler H.L., Cauthen G.M., Kelly G.D. Tuberculosis in the United States. J.A.M.A. 262:1989;385-389.
147. Riedler H.L., Cauthen G.M., Comstock G.W., Snider D.E. Jr. Epidemiology of tuberculosis in the United States. Epidemiol. Rev. 11:1989;79-98.
148. Risdahl J.M., Peterson K., Chao C.C., Pijoan C., Molitor T.W. Effects of morphine dependence on the pathogenesis of swine herpesvirus infection. J. Infect. Dis. 167:1993;1281-1287.
149. Risdahl, J.M., Peterson, P.K., Molitor, T.W., 1995. Opiates, infection and immunity. In: Friedman, H., Klein T.W., Specter, S. (Eds.), Drugs of Abuse, Immunity and Infections. CRC Press, Boca Raton, FL, pp. 1-42.
150. Rojavin M., Szabo I., Bussiere J.L., Rogers T.J., Adler M.W., Eisenstein T.K. Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci. 53:1993;997-1006.
151. Ronald P.J., Robertson J.R., Elton R.A. Continued drug use and other cofactors for progression to AIDS among injection drug users. AIDS. 8:1994;339-343.
152. Rouviex B., Veyries M.L. Effects of morphine on murine infection with Friend retrovirus. Bull. Acad. Natl. Med. 179:1995;1069-1080.
153. Ruff M.R., Wahl S.M., Mergenhagen S., Pert C.B. Opiate receptor-mediated chemotaxis of human monocytes. Neuropeptides. 5:1985;363-366.
154. Safani M., Blair J., Ross D., Waki R., Li C., Libby G. Prospective, controlled, randomized trial of naloxone infusion in early haemodynamic septic shock. Crit. Care Med. 17:1989;1004-1009.
155. Salvador-Grande F., Saiz-Monzon L., De la Torre P., Yuguero del Moral L., Lorenzo-Gonzalez J.F., Mijan de la Torre A. Acaulous cholecystitis and intestinal cryptosporidiosis, frequent association with HIV patients. Rev. Esp. Enferm. Dig. 87:1995;593-596.
156. Sapira J.D. The narcotic addict as a medical patient. Am. J. Med. 45:1968;555-588.
157. Sapira, J.D., Cherubin, C.C., 1975. Drug Abuse, A Guide for the Clinician. American Elsevier Publishing, New York, NY, pp. 1-280.
158. Sapira J.D., Ball J., Penn H. Causes of death among institutionalized narcotic addicts. J. Chron. Dis. 22:1970;733-742.
159. Scheidegger C., Zimmerli W. Infectious complications in drug addicts, seven year review of 269 hospitalized narcotic abusers in Switzerland. Rev. Infect. Dis. 3:1989;486-493.
160. Schinaia, N.F., Chiarotti, L., 1990. The progression to AIDS in the Italian haemophilia population over a six year period. VI International Conference on AIDS, Final Program and Abstracts, Vol. 1, [abstract Th.C.38], June 20-21. San Francisco, CA, p. 143.
161. Schwebke J., Calsyn D., Shriver K., Saxon A., Kleyn J., Oluch-Mitchell E., Olmsted L., Fisher L.D., Krone M., Ashley R., Stamm W., Swenson P., Holmes K.K. Prevalence and epidemiologic correlates of human T-cell lymphotropic virus infection among intravenous drug users. J. Infect. Dis. 169:1994;962-967.
162. Schweitzer C., Keller F., Schmitt M.P., Jaeck D., Adloff M., Schmitt C., Royer C., Kirn A., Aubertin A.M. Morphine stimulates HIV replication in primary cultures of human kupffer cells. Res. Virol. 142:1991;189-195.
163. Selwyn P.A., Hartel D., Lewis V.A. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:1989;545-550.
164. Selwyn P.A., Alcabes P., Hartel D.et al. Clinical manifestations and predictors of disease progression in drug users with HIV infections. N. Engl. J. Med. 327:1992;1697-1703.
165. Sepkowitz K.A., Raffalli J., Riley L., Kiehn T.E., Armstrong D. Tuberculosis in the AIDS era. Clin. Microbiol. Rev. 8:1995;180-199.
166. Shattock R.J., Friedland J.S., Griffin G.E. Phagocytosis of Mycobacterium tuberculosis modulates human immunodeficiency virus replication in human monocytic cells. J. Gen. Virol. 75:1994;849-856.
167. Singh P.P., Singh S., Dutta G.P., Srimaal R.C. Immunomodulation by morphine in Plasmodium berghei-infected mice. Life Sci. 54:1994;331-339.
168. Sobel, J.D., 1991. Acquired immunodeficiency syndrome in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 43-379.
169. Specter S. Drugs of abuse and infectious diseases. J. Fla. Med. Assoc. 81:1994;485-487.
170. Squinto S.P., Mondal D., Block A.L., Prakash O.M. Morphine induced transactivation of HIV-1 LTR in human neuroblastoma cells. AIDS Res. Hum. Retrovir. 6:1990;1163-1168.
171. Starec M., Rouveix B., Sinet M., Chau F., Desforges B., Pocidalo J.J., Lechat P. Immune status and survival of opiate- and cocaine-treated mice infected with Friend virus. J. Pharmacol. Exp. Ther. 259:1991;745-750.
172. Steinberg et al., 1997.
173. Stoneburner R.L., Des Jarlais D.C., Benezra D., Gorelkin L., Sotheran J.L., Friedman S.R., Schultz S., Marmor M., Mildvan D., Maslanlky R. A larger spectrum of severe HIV-1 related diseases in intravenous drug users in New York City. Science. 242:1988;916-919.
174. Sunstrum, J., 1991. Central nervous system infections in intravenous drug abusers. In: Levine, D.P., Sobel, J.B. (Eds.), Infections in Intravenous Drug Abusers. Oxford Univ. Press, New York, NY, pp. 152-166.
175. Tedeschi, G., 1899. Ricerche sperimentali sull azione della morfina sullo sviluppo e sul decorso della enfezione tubercolare. Riforma Med., p. 4/p. 638/p. 651/p. 663.
176. Terry, M.D., Pellens, M., 1928. The Opium Problem. The Bureau of Social Hygiene, New York, NY, pp. 53-93.
177. Thiede H., Harris N.V., McGough J.P., Roberts B., Khabbaz R.F., Kaplan J.E. Presence of HTLV types I and II among drug users in King County, Washington. West. J. Med. 160:1994;540-544.
178. Thomas D.L., Zenilman J.M., Alter H.J., Shih J.W., Galai N., Carella A.V., Quinn T.C. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J. Infect. Dis. 171:1995;768-775.
179. Tubaro E., Borelli G., Croce C., Cavallo G., Santiangeli C. Effect of morphine on resistance to infection. J. Infect. Dis. 148:1983;656-666.
180. Tubaro E., Avico U., Santiangeli C., Zuccaro P., Cavallo G., Pacifici R., Croce C., Borelli G. Morphine and methadone impact on human phagocytic physiology. Int. J. Immunopharmacol. 7:1985;865-874.
181. Tubaro E., Santiangeli C., Belogi L., Borelli G., Cavallo G., Croce C., Avico U. Methadone vs. morphine, comparison of their effect on phagocytic functions. Int. J. Immunopharmacol. 9:1987;79-88.
182. van Ameijden E.J., van den Hoek A.J., van Haastrecht H.J., Coutinho R.A. Trends in sexual behavior and the incidence of sexually transmitted diseases and HIV among drug-using prostitutes, Amsterdam, 1986-1992. AIDS. 8:1994;213-221.
183. Van der Laan J.W., Krajnc E.I., Krajnc-Franken M.A., van Loveren H. Immunotoxilogical screening of morphine and methadone in an extended 28-day study in rats. Int. J. Immunopharmacol. 17:1995;535-543.
184. Verhoef J. Prevention of infections in the neutropenic patient. Clin. Infect. Dis. 17:1993;S359-367.
185. Veyries M.L., Sinet M., Desforges B., Rouviex B. Effects of morphine on the pathogenesis of murine Friend retrovirus infection. J. Pharmacol. Exp. Ther. 272:1995;498-504.
186. Vlahov D., Anthony J.C., Celentano D., Soloman L., Chowdhury N. Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982-1987. Am. J. Drug Alcohol Abuse. 17:1991;39-48.
187. Watson R.R. LP-BM5, a murine model of acquired immunodeficiency syndrome, role of cocaine, morphine, alcohol and carotenoid in nutritional immunomodulation. J. Nutr. 122:1992;744-748.
188. Watson R.R., Nguyen T.H. Suppression by morphine and ethanol of tumor cell cytotoxic activity released by macrophages from retrovirally infected mice upon in vitro stimulation by beta carotene. Prog. Clin. Biol. Res. 325:1990;79-91.
189. Watson R.R., Prabhala R.H., Darban H.R., Yahya M.D., Smith T.L. Changes in lymphocyte and macrophage subsets due to morphine and ethanol treatment during a retrovirus infection causing murine AIDS. Life Sci. 43:1988;5-11.
190. Weber, R., Ledergerber, B., Opravil, M., Luthy, R., 1990. Cessation of intravenous drug use reduces progression of HIV-infection in HIV+drug users. VI International Conference on AIDS, Final Program and Abstracts, Vol. 1, [abstract Th.C.36], June 20-21, San Francisco, CA, p. 142.
191. Whipham T. Fatal pleuropneumonia in the case of a man aged 56, addicted to the abuse of morphia, alcohol and bromide of potassium. Trans. Clin. Soc. London. 8:1875;108-117.
192. Yap P.L. Prevention of infection in patients with B cell defects, focus on intravenous immunoglobulin. Clin. Infect. Dis. 17:1993;S372-375.
193. Yeager M.P., Yu C.T., Campbell A.S., Moschella M., Guyre P.M. Effect of morphine and beta-endorphin on human Fc receptor-dependent and natural killer cell functions. Clin. Immunol. Immunopathol. 62:1992;336-343.
194. Yeager M.P., Colacchio T.A., Yu C.T., Hildebrandt L., Howell A.L., Weiss J., Guyre P.M. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 83:1995;500-508.
195. Zbrog Z., Luciak M., Tchorzewski H., Pokoca L. Modification of some lymphocyte functions in vitro by opioid receptor agonists and antagonist in chronic uremic patients and healthy subjects. Int. J. Immunopharmacol. 13:1991;475-483.
196. Zoloth S.R., Safyer S., Rosen J., Michaels D., Alcabes P., Bellin E., Braslow C. Anergy compromises screening for tuberculosis in high-risk populations. Am. J. Pub. Hlth. 83:1993;749-751.